Form 4: Cingulate Inc. Executive Receives Stock Options as Part of 2024 Bonus

Raul R. Silva, EVP and CSO of Cingulate Inc., was granted stock options as part of his 2024 bonus.

Summary

• Raul R. Silva, an Executive Vice President and Chief Strategy Officer at Cingulate Inc., received 2,748 stock options.
• These options were granted on January 17, 2025, as part of his 2024 bonus.
• The options have an exercise price of $4.76 per share and expire on January 17, 2035.
• The options are exercisable immediately.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management with shareholder interests. There are no negative implications.

Positives

• The granting of stock options to a key executive like Raul R. Silva can be seen as a positive incentive and alignment of interests with shareholders.
• The options have a 10 year term, which is a long term incentive.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard practice for incentivizing executives in publicly traded companies, particularly in the biotech sector.
• The vesting schedule and exercise price are typical for such grants, although the specific terms can vary based on company performance and individual agreements.
• Companies like Amgen, Gilead, and Biogen also use stock options as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may view this as a positive sign of aligning executive interests with company performance.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, executive compensation, insider trading, Cingulate Inc., Raul R. Silva, EVP, CSO